Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol 2023 Mar 30:ljad022. doi: 10.1093.
PMID: 36994947